Molly He, Ph.D. was recently appointed as the venture partner in Foresite Capital. Foresite Capital is healthcare growth equity and Molly He will bring into the business more than 15 years of genomic research and development and pharmaceutical experience. In an Interview on the Chief executive and Managing director of Foresite Capital Jim Tananbaum as […]
Molly He, Ph.D. was recently appointed as the venture partner in Foresite Capital. Foresite Capital is healthcare growth equity and Molly He will bring into the business more than 15 years of genomic research and development and pharmaceutical experience.
In an Interview on the Chief executive and Managing director of Foresite Capital Jim Tananbaum as he welcomed her said “Dr. He holds a high esteem respect as a scientist researcher dealing with next-generation sequencing. He also added that with years of extensive research and expertise in drug development and genomics and years of tractable excellent record of leadership; she will be an added value to Foresite. According to Jim, Dr. He will play a significant role in the company as they diversify the company portfolio and expand.
Dr. He before joining Foresite healthcare company she was the senior director at Illumina heading the scientific research team. Before Illumina, the Dr. worked at Pacific Biosciences where she held the position of head of protein sciences. Here she was responsible for the development of protein reagents for the single molecular sequencing chemistry in real-time. Earlier days of her career, she spent more than ten years dealing with structural based small molecule drugs and design of antibody targeting immune diseases and cancer. Dr. Molly He has a biochemistry bachelor’s degree from Nankai University, and from the University of California, she has a Ph.D. in Protein Biophysics. Additionally, she has published more than 20 papers with more than 20 patent applications. In Next-generation sequencing field she has issued patent and personalized medicine.
In her opening speech, the Dr. praised Foresite for the unmatched status of investing in innovative and exciting healthcare companies. She said it’s an honor to join Foresite dynamic team and help it grow its next-generation sequencing portfolio. Next-generation sequencing is a medical field with the potential of creating breakthroughs in drug discovery and clinical research.
Dr. Jim Tananbaum CEO and founder of Foresite capital management have led successful healthcare investments in more than 21 companies including Jazz Pharmaceuticals and Amerigroup among others. He is a Harvard medical school graduate with M.D, B.S.E.E of Yale and Harvard Business School M.B.A. He has also served on different advisory boards.